The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | bb21217: next gen anti-BCMA CAR-T for R/R MM
Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, gives an update on the results from an ongoing phase I clinical study (CRB-402; NCT03274219) of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in heavily pretreated relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
